Management of immunocompetent patients with primary central nervous system lymphoma

Clinical Lymphoma and Myeloma

Volumn 9, Issue 5, 2009, Pages 353-364

  Chimienti, Emanuela ^a   Spina, Michele ^a   Vaccher, Emanuela ^a   Tirelli, Umberto ^a  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Corticosteroids; Methotrexate; Neurotoxicity; Radiation therapy; Temozolomide; Topotecan

Indexed keywords

BLEOMYCIN; BUSULFAN; CARMUSTINE; CHLORMETHINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; IBRITUMOMAB TIUXETAN; IDARUBICIN; MELPHALAN; METHOTREXATE; METHYLPREDNISOLONE; PEMETREXED; PREDNISONE; PROCARBAZINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RITUXIMAB; TEMOZOLOMIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRAIN RADIATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG PENETRATION; HUMAN; IMMUNOCOMPETENCE; KIDNEY FAILURE; LEUKOENCEPHALOPATHY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL NEUROPATHY; POSITRON EMISSION TOMOGRAPHY; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PROGNOSIS; RECURRENCE RISK; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 70350647298     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.070     Document Type: Review

References (82)

1. Batchelor T, Loeffler JS. Primary CNS lymphoma. J Clin Oncol 2006; 24:1281-1288.
2. Central Brain Tumor Registry of the United States. Primary brain tumors in the United States 1995-1999. Chicago, III: CBTRUS, 2002-2003.
3. Ferreri AJ, Abrey LE, Blay JY, et al. Summary statement on primary central nervous system lymphomas from the Eighth International Conference on Malignant Lymphoma, Lugano, Switzerland, June 12 to 15, 2002. J Clin Oncol 2003; 21:2407-2414.
4. Haldorsen IS, Krossnes BK, Aarseth JH, et al. Increasing incidence and continued dismal outcome in primary central nervous system lymphoma in Norway 1989- 2003, time trends in a 15-year National survey. Cancer 2007; 110:1803-1814.
5. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin's lymphoma. Cancer 2002; 95:1504-1510.
6. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United. Int J Cancer 2008; 123:187-194.
7. Ferreri AJ, Reni M. Primary central nervous system lymphoma. Crit Rev Oncol Hematol 2007; 63:257-268.
8. Rosenfeld SS, Hoffman JM, Coleman RE, et al. Studies of primary central nervous system lymphoma with fluorine-18-fluorodeoxyglucose positron emission tomography. J Nucl Med 1992; 33:532-536.
9. Palmedo H, Urbach H, Bender H, et al. FDG-PET in immunocompetent patients with primary central nervous system lymphoma: correlation with MRI and clinical follow-up. Eur J Nucl Med Mol Imaging 2006; 33:164-168.
10. Karantanis D, O'eill BP, Subramaniam RM, et al. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 2007; 28:834-841.
11. Shenkier TN, Blay JY, O'Neill BP, et al. Primary CNS lymphoma of T cell origin: a descriptive analysis from the international primary CNS lymphoma collaborative group. J Clin Oncol 2005; 23:2233-2239.
12. Tu PH, Gianni C, Judkins AR, et al. Clinicopathologic and genetic profile of intracranial marginal zone lymphoma: a primary low-grade CNS lymphoma that mimics meningioma. J Clin Oncol 2005; 23:5718-5727.
13. Smith JR, Braziel RM, Paoletti S, et al. Expression of B cell attracting chemokine 1 (CXCL 13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101:815-821.
14. Braaten KM, Betensky RA, de Leval L, et al. BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma. Clin Cancer Res 2003; 9:1063-1069.
15. Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphoma: analysis of 83 cases. Blood 2006; 107:190-196.
16. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B cell lymphoma identified by gene expression profiling. Nature 2000; 403:503-511.
17. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004.103:275-282.
18. Ferreri AJ, Reni M, Zoldan MC, et al. Importance of complete staging in non- Hodgkin lymphoma presenting as a cerebral mass lesion. Cancer 1996; 77:827-833.
19. O'Neill BP, Dinapoli RP, Kurtin PJ, et al. Occult systemic non-Hodgkin's lymphoma (NHL) in patients initially diagnosed as primary central nervous system lymphoma (PCNSL): how much staging is enough? J Neurooncol 1995; 25:67-71.
20. Nelson DF, Martz KL, Bonner H, et al. Non-Hodgkin's lymphomas of the brain: can high dose, large volume radiation therapy improve survival? Report of a prospective trial by the radiation therapy oncology group (RTOG): RTOG8315. Int J Radiat Oncol Biol Phys 1992; 23:9-17.
21. Hayakawa T, Takakura K, Abe H, et al. Primary central nervous system lymphoma in Japan: a retrospective, cooperative study by CNS-Lymphoma Study Group in Japan. J Neurooncol 1994; 19:197-215.
22. Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol 2005; 23:5034-5043.
23. DeAngelis LM. Primary CNS lymphoma: treatment with combined chemotherapy and radiotherapy. J Neurooncol 1999; 43:249-257.
24. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol 1999; 43:241-247.
25. Murray K, Kun L, Cox J. Primary malignant lymphoma of the central nervous system. Results of treatment of 11 cases and review of the literature. J Neurosurg 1986; 65:600-607.
26. Pollack IF, Dade Lunsford L, Flickinger JC, et al. Prognostic factors in the diagnosis and treatment of primary central nervous system lymphoma. Cancer 1989; 63:939-947.
27. Reni M, Ferreri AJ, Garancini MP, et al. Therapeutic management of primary central nervous system lymphoma in immunocompetent patients: results of a critical review of the literature. Ann Oncol 1997; 8:227-234.
28. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in retrospective series. J Clin Oncol 1998; 16:864-871.
29. Boiardi A, Silvani A. Primary cerebral non-Hodgkin lymphoma (PCNSL): a review of new trends in management. Ital J Neurol Sci 1997; 18:1-7.
30. Hochberg FH, Loeffler JS, Prados M. The therapy of primary brain lymphoma. J Neurooncol 1991; 10:191-201.
31. O'Neill BP, O'Fallon JR, Earle JD, et al. Primary central nervous system non- Hodgkin's lymphoma: survival advantages with combined initial therapy? Int J Radiat Oncol Biol Phys 1995; 33:663-673
32. Mead GM, Bleehen NM, Gregor A, et al. A medical research council randomized trial in patients with primary cerebral non-Hodgkin lymphoma. Cancer 2000; 89:1359-1370.
33. Blay JY, Ongolo-Zogo P, Sebban C, et al. Primary cerebral lymphomas: unsolved issues regarding first-line treatment, follow-up, late neurological toxicity and treatment of relapses. The FNCLCC. French Fédération Nationale des Centres de Lutte contre le Cancer. Ann Oncol 2000; 11(suppl 1):39-44.
34. Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol 2000; 18:3144-3150.
35. Gavrilovic IT, Hormigo A, Yahalom J, et al. Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. J Clin Oncol 2006; 24:4570-4574.
36. Guha-Thakurta N, Damek D, Pollack C, et al. Intravenous methotrexate as initial treatment for primary central nervous system lymphoma: response to therapy and quality of life of patients. J Neurooncol 1999; 43:259-268.
37. Sarazin M, Ameri A, Monjour A, et al. Primary central nervous system lymphoma: treatment with chemotherapy and radiotherapy. Eur J Cancer 1995; 31A:2003-2007.
38. Hiraga S, Arita N, Ohnishi T, et al. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas. J Neurosurg 1999; 91:221-230.
39. Korfel A, Thiel E. Successful treatment of non-Hodgkin's lymphoma of the central nervous system with BPMD chemotherapy followed by radiotherapy. Leuk Lymphoma 1998; 30:609-617.
40. Dent S, Eapen L, Girard A, et al. PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. J Neurooncol 1996; 28:25-30.
41. Bessell EM, Graus F, Punt JA, et al. Primary non-Hodgkin's lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy. J Clin Oncol 1996; 14:945-954.
42. Blay JY, Bouhour C, Carrie C, et al. The C5R protocol: a regimen of high-dose chemotherapy and radiotherapy in primary cerebral non-Hodgkin lymphoma of patients with no known cause of immunosuppression. Blood 1995; 86:2922-2929.
43. Brada M, Hjiyiannakis D, Hines F, et al. Short intensive primary chemotherapy and radiotherapy in sporadic primary CNS lymphoma (PCL). Int J Radiat Oncol Biol Phys 1998; 40:1157-1162
44. Brada M, Dearnaley D, Horwich A, et al. Management of primary cerebral lymphoma with initial chemotherapy: preliminary results and comparison with patients treated with radiotherapy alone. Int J Radiat Oncol Biol Phys 1990; 18:787-792.
45. Ferreri AJ, Dell'Oro S, Foppoli M, et al. MATILDE regimen followed by radiotherapy is an active strategy against primary CNS lymphomas. Neurology 2006; 66:1435-1438.
46. Shah GD, Yahalom J, Correa DD, et al. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma [published erratum in: J Clin Oncol 2008; 26:340]. J Clin Oncol 2007; 25:4730-4735.
47. Ekenel M, Iwamoto FM, Ben-Porat LS, et al. Primary central nervous system lymphoma: the role of consolidation treatment after a complete response to high-dose methotrexate-based chemotherapy. Cancer 2008; 113:1025-1031.
48. Ferreri AJ, Reni M, Foppoli M, et al. High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in for patients with primary CNS lymphoma: a randomised phase 2 trial. Lancet 2009 Sep 18. [Epub ahead of print].
49. Abrey LE, Moskowitz CH, Mason WP, et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to-treat analysis. J Clin Oncol 2003; 21:4151-4156.
50. Illerhaus G, Marks R, Ihorst G, et al. High-dose chemotherapy with autologous stem-cell transplantation and hyperfractionated radiotherapy as first-line treatment of primary CNS lymphoma. J Clin Oncol 2006; 24:3865-3870.
51. Cheng T, Forsyth P, Chaudhry A, et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31:679-685.
52. Colombat P, Lemevel A, Bertrand P, et al. High-dose chemotherapy with autologous stem-cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 2006; 38:417-420.
53. Montemurro M, Kiefer T, Schüler F, et al. Primary central nervous system lymphoma treated with high-dose methotrexate, high-dose busulfan/thiotepa, autologous stem-cell transplantation and response-adapted whole-brain radiotherapy: results of the multicenter Ostdeutsche Studiengruppe Hamato-Onkologie OSHO-53 phase II study. Ann Oncol 2007; 18:665-671.
54. Illerhaus G, Muller F, Feuerhake F, et al. High-dose chemotherapy and autologous stem-cell transplantation without consolidating radiotherapy as first-line treatment for primary lymphoma of the central nervous system. Haematologica 2008; 93:147-148.
55. Soussain C, Hoang-Xuan K, Taillandier L, et al. Intensive chemotherapy followed by hematopoietic stem-cell rescue for refractory and recurrent primary CNS and intraocular lymphoma: Société Francaise de Greffe de Moelle Osseuse-Thérapy Cellulaire. J Clin Oncol 2008; 26:2512-2518.
56. Correa DD, Maron L, Harder H, et al. Cognitive functions in primary central nervous system lymphoma: literature review and assessment guidelines. Ann Oncol 2007; 18:1145-1151.
57. Correa DD, Rocco-Donovan M, Deangelis LM, et al. Prospective cognitive follow-up in primary CNS lymphoma patients treated with chemotherapy and reduced-dose radiotherapy. J Neurooncol 2009; 91:315-321.
58. Bessell EM. Hoang-Xuan K, Ferreri AJ, et al. Primary central nervous system lymphoma: biological aspects and controversies in management. Eur J Cancer 2007; 43:1141-1152. (Pubitemid 46590731)
59. O'Neill BP, Habermann TM, Witzig TE, et al. Prevention of recurrence and prolonged survival in primary central nervous system lymphoma (PCNSL) patients treated with adjuvant high-dose methylprednisolone. Med Oncol 1999; 16:211-215.
60. Ferreri AJ, Assanelli A, Crocchiolo R, et al. Central nervous system dissemination in immunocompetent patients with aggressive lymphomas: incidence, risk factors and therapeutic options. Hematol Oncol 2009; 27:61.70.
61. Neuwelt EA, Goldman DL, Dahlborg SA, et al. Primary CNS lymphoma treated with osmotic blood-brain barrier disruption: prolonged survival and preservation of cognitive function. J Clin Oncol 1991; 9:1580-1590.
62. Herrlinger U, Brugger W, Bamberg M. PVC salvage chemotherapy for recurrent primary CNS lymphoma. Neurology 2000; 54:1707-1708.
63. Krogh-Jensen M, d'Amore F, Jensen MK, et al. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Ann Oncol 1994; 5:349-354.
64. Socie G, Piprot-Chauffat C, Schlienger M, et al. Primary lymphoma of the central nervous system: an unresolved therapeutic problem. Cancer 1990; 65:322-326.
65. Reni M, Ferreri AJ, Villa E. Second-line treatment for primary central nervous system lymphoma. Br J Cancer 1999; 79:530-534.
66. Soussain C, Suzan F, Hoang-Xuan K, et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19:742-749.
67. Reni M, Mazza E, Foppoli M, et al. Primary central nervous system lymphomas: salvage treatment after failure to high-dose methotrexate. Cancer Lett 2007; 258:165-170.
68. Reni M, Zaja F, Mason W, et al. Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer 2007; 96:864-867.
69. Wong ET, Tishler R, Barron L, et al. Immunochemotherapy with rituximab and temozolomide for central nervous system lymphoma. Cancer 2004; 101:139-145.
70. Enting RH, Demopoulos A, DeAngelis LM, et al. Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide. Neurology 2004; 63:901-903.
71. Fischer L, Thiel E, Klasen HA, et al. Prospective trial on topotecan salvage therapy in primary CNS lymphoma. Ann Oncol 2006; 17:1141-1145.
72. Voloschin AD, Betensky R, Wen PY, et al. Topotecan as salvage therapy for relapsed or refractory primary central nervous system lymphoma. J Neurooncol 2008; 86:211-215.
73. Altman JK, Tellez C, Chandler J, et al. Phase II trial of recurrent primary CNS lymphoma (PCNSL) treated with pemetrexed. J Clin Oncol 2008; 26(15 suppl):107s (Abstract 2075).
74. Iwamoto FM, Schwartz J, Pandit-Taskar N, et al. Study of radiolabeled Indium- 111 and Yttrium-90 Ibritumomab tiuxetan in primary central nervous system lymphoma. Cancer 2007; 110:2528-2534.
75. Maza S, Kiewe F, Munz DL et al. First report on a prospective trial with yttrium- 90-labeled Ibritumomab Tiuxetan (ZevalinTM) in primary CNS lymphoma. Neuro Oncol 2009; 11:423-429.
76. Schlegel U, Oehring R, Blumcke I. Neurologic sequelae of treatment of primary CNS lymphomas. J Neurooncol 1999; 43:277-286.
77. Abrey LE, De Angelis LM, Yahalam J. Long-term survival in primary CNS lymphoma. J Clin Oncol 1998; 16:859-863.
78. Chamberlain MC, Levin VA. Primary central nervous system lymphoma: a role for adjuvant chemotherapy. J Neurooncol 1992; 14:271-275.
79. Dahlborg SA, Henner WD, Crossen JR, et al. Non-AIDS primary CNS lymphoma: first example of a durable response in a primary brain tumor using enhances chemotherapy delivery without cognitive loss and without radiotherapy. Cancer J Sci Am 1996; 2:166-174.
80. Ferreri A, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol 2003; 21:266-272.
81. Abrey LE, Ben-Porat L, Panageas KS. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol 2006; 24:5711-5715.
82. Ferreri AJ, Reni M, Cavalli F. Primary CNS lymphomas prognosis. J Clin Oncol 2007; 25:4322-4325.